Induction of γ-glutamylcysteine synthetase gene expression by platinum drugs in peripheral mononuclear cells of lung cancer patients

Annals of Oncology

Volumn 10, Issue 4, 1999, Pages 455-460

  Oguri, T ^b   Fujiwara, Y ^a   Miyazaki, M ^b   Takahashi, T ^b   Kurata, T ^b   Yokozaki, M ^b   Ohashi, N ^b   Isobe, T ^b   Katoh, O ^b   Yamakido, M ^b  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

cMOAT; MRP; Platinum drug resistance; GCS heavy subunit; GCS light subunit

Indexed keywords

CARRIER PROTEIN; DNA TOPOISOMERASE; GLUTAMATE CYSTEINE LIGASE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; PLATINUM;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME SUBUNIT; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG CARCINOMA; MALE; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL;

EID: 0032933546     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008317502977     Document Type: Article

References (31)

1. Fujiwara Y, Sugimoto Y, Kasahara K et al. Determinants of drug response in a cisplatin-resistant human lung cancer cell line. Jpn J Cancer Res 1990; 81: 527-35.
2. Godwin AK, Meister A, O'Dwyer PJ et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992; 89: 3070-4.
3. Hamaguchi K, Godwin AK, Yakushiji M et al. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. Cancer Res 1993; 53: 5225-32.
4. Goto S, Yoshida K, Morikawa T et al. Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells. Cancer Res 1995; 55: 4297-301.
5. Kurokawa H, Ishida T, Nishio K et al. γ-Glutamylcysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance. Biochem Biophys Res Commun 1995; 216: 258-64.
6. Ishikawa T, Ali-Osman F. Glutathione-associated cis-diammine-dichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. J Biol Chem 1993; 268: 20116-25.
7. Ishikawa T, Wright CD, Ishizuka H. GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum (II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation. J Biol Chem 1994; 269: 29085-93.
8. Fujii R, Mutoh M, Sumizawa T et al. Adenosine triphosphate-dependent transport of leukotriene C4 by membrane vesicles prepared from cisplatin-resistant human epidermoid carcinoma tumor cells. J Natl Cancer Inst 1994; 86: 1781-9.
9. Chuman Y, Chen Z-S, Sumizawa T et al. Characterization of the ATP-dependent LTC4 transporter in cisplatin-resistant human KB cells. Biochem Biophys Res Commun 1996; 226: 158-65.
10. Jedlitschky G, Leier I, Buchholz U et al. ATP-dependent transport of glutathione S-conjugates by multidrug resistance-associated protein. Cancer Res 1994; 54: 4833-6.
11. Leier I, Jedlitschky G, Buchholz U et al. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 1994; 269: 27808-10.
12. Müller M, Meijer C, Zaman GJR et al. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 1994; 91: 13033-7.
13. Bücher M, König J, Brom M et al. cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats. J Biol Chem 1996; 271; 15091-8.
14. Madon J, Eckhardt U, Gerloff T et al. Functional expression of the rat liver canalicular isoform of the multidrug resistance-associated protein. FEBS Lett 1997; 406: 75-8.
15. Oguri T, Fujiwara Y, Isobe T et al. Expression of γ-glutamylcysteine synthetase (γ-GCS) and multidrug resistance-associated protein (MRP), but not human canalicular multispecific organic anion transporter (cMOAT), genes correlates with exposure of human lung cancers to platinum drugs. Br J Cancer 1998; 77: 1089-96.
16. Ohashi N, Fujiwara Y, Yamaoka N et al. No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer. Jpn J Cancer Res 1996; 87: 1280-7.
17. Miyazaki M, Fujiwara Y, Takahashi T et al. Limited-sampling models for estimation of the carboplatin area under the curve. Anticancer Res 1997; 17: 4571-6.
18. Fujiwara Y, Takahashi T, Yamakido M et al. Re: Prediction of carboplatin clearance from standard morphological and biological patient characteristics (Letter). J Natl Cancer Inst 1997; 89: 260-1.
19. Miyazaki M, Fujiwara Y, Isobe T et al. The relationship between carboplatin AUC and serum thrombopoietin kinetics in patients with lung cancer. Anticancer Res 1999 (in press).
20. Tothill P, Klys HS, Matheson LM. The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy. Eur J Cancer 1992; 28; 1358-61.
21. O'Dwyer PJ, Szarka CE, Yao K-S et al. Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. J Clin Invest 1996; 98; 1210-7.
22. Tew KD, Monks A, Barone L et al. Glutathione-associated enzymes in the human cell lines of the National Cancer Institute drug screening program. Mol Pharmacol 1996; 50: 149-59.
23. Meister A. Glutathione and thioredoxin: Thiols in sigal transduction and gene regulation; (3) Glutathione biosynthesis and its inhibition. Methods Enzymol 1995; 252: 26-30.
24. Huang C-S, Chang L-S, Anderson ME et al. Catalystic and regulatory properties of the heavy subunit of rat kidney γ-glutamylcysteine synthetase. J Biol Chem 1993; 268: 19675-80.
25. Ishikawa T, Bao J-J, Yamane Y et al. Coordinated induction of MRP/GS-X pump and γ-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 1996; 271: 14981-8.
26. Kauffmann HM, Keppler D, Kartenbeck J et al. Induction of cMrp/cMoat gene expression by cisplatin, 2-acetylaminofluorene, or cycloheximine in rat hepatocytes. Hepatology 1997; 26: 980-5.
27. Koike K, Kawabe T, Tanaka T et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 1997; 57: 5475-9.
28. Saijo N. Clinical trials of irinotecan hydrochloride (CPT, campto injection, topotecin injection) in Japan. Ann NY Acad Sci 1996; 13: 292-305.
29. Rowinsky EK, Kaufmann SH, Barker SD et al. Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 1996; 14: 3074-84.
30. Kudoh S, Fujiwara Y, Takada Y et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J Clin Oncol 1998; 16: 1068-74.
31. Fukuda M, Nishio K, Kanzawa F et al. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small-cell lung cancer cells. Cancer Res 1996; 56: 789-93.